Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.
about
The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinomaMultisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Determinants of seropositivity among HPV-16/18 DNA positive young women.Seroprevalence of 34 human papillomavirus types in the German general population.Evidence for vertical transmission of HPV from mothers to infantsProgesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy womenSerological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile.Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohortNatural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study.Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionHuman papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational studyHigh-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study)Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in menPrevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in menEvaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.The immune response to papillomavirus during infection persistence and regression.Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global reviewDeterminants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa RicaVaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018Sexually transmissible infections and prostate cancer riskHuman papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species.Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British ColumbiaBias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses.High-risk human papillomavirus seroprevalence in men and women of six different ethnicities in Amsterdam, the Netherlands: The HELIUS study.Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.The use of human papillomavirus seroepidemiology to inform vaccine policy.Risk factors associated with human papillomavirus infection in two populations from Rio de Janeiro, Brazil.Smoking and subsequent human papillomavirus infection: a mediation analysis.Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico.
P2860
Q28387851-A334BE2A-8329-4049-B2DF-631B5CF384ECQ30354637-776B16FF-0305-4900-9985-B70B8CF36837Q30986936-6C862D7E-3F09-451C-81F8-C3F23DBCBCBFQ33345224-BA77BAEC-B10A-4DBC-BADE-7D96CFB08609Q33726704-3359B0F1-2E4A-46E6-BDE8-7972F5CA8726Q33768747-E61B14FC-FD24-47F3-9E44-114E4FB90066Q33880956-A98A088A-5291-485D-98AE-6DEFD7C32968Q34310582-FF075107-A070-44E4-A4EE-49BD85DC884BQ34366883-E6517509-1519-404D-97DB-2E285C799B16Q34546550-81E88225-73BA-4181-B962-0DE7E00564BDQ34587057-14E5E91F-4503-44CE-9E6C-C4741EDECEFFQ34601418-7EF26110-A1CD-43C5-842C-69434D735650Q34970731-E77BEDED-7C85-4B6F-975B-A7FF82C16B80Q34987731-BD379BC8-6F90-4EC9-85C9-EC515FDC7639Q35016793-9A7452E1-956C-4193-86F7-45B598365FDBQ35088658-840DEFAA-4C43-486E-916A-7B12B5CA0685Q35596329-17F775A7-9757-4B46-A2F3-E4C0620D2CBFQ35659008-806FB4B7-245E-4B87-BD39-B637623C8A36Q36302928-352E187E-E933-4101-AE7F-32E60D75F29DQ36327051-757248F2-CB40-4381-83DA-2A6FF312A684Q36422593-6350118C-EFF0-495A-AC59-AA1DEB802FB3Q36452565-224F4343-A159-4659-B18B-75E7D67F8765Q36539107-6F4769D0-5B78-4A42-8285-CF0E755D2734Q36540399-C2FC9014-8DEC-46D6-A120-0F8F1B050284Q36565494-FCE60AB3-9B87-4D3A-B27D-5D52E6D8E787Q36609068-6769782D-E9DE-4D2A-82B7-948C1A6FECCDQ36695693-B685BFA3-0823-4728-8821-6DB2780AA6A5Q36743080-A23F945F-6D12-4163-BA83-7EEB73CF9227Q36920062-06E0AB5F-6172-4888-AA2A-7953CDA4ABD4Q37349373-2E210A81-BB35-45D7-8E96-EDFB56A330CFQ37397990-F2E6B4B9-699A-44FC-9D8B-B4044628E855Q37450852-FCCC36AE-12FD-43C2-B12E-70F1442092DCQ39122093-50762862-08D4-4BE4-AA98-F3B6636372BAQ39873630-D529F812-BE72-4CDC-8BD2-32EC661D9629Q40117849-DB8EF01F-64DA-4849-A561-AD0C241E4D62Q40571982-B56D32E0-5DDD-4AE4-AFC1-49FBD9DB605BQ43013653-59A02143-D09A-406B-BB7D-E4120FC8AD59Q43252098-C1C94FE9-C0C4-43BE-B1FD-77E2EA06FF37Q50137874-25C268BE-37C1-4B18-B6E5-FF8B57DADF53Q53430838-9A345091-C198-4F3B-B3CB-8B48B0F35252
P2860
Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@ast
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@en
type
label
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@ast
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@en
prefLabel
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@ast
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@en
P2093
P2860
P356
P1476
Seroprevalence of human papill ...... of 10000 women in Costa Rica.
@en
P2093
A C Rodriguez
A Hildesheim
M C Bratti
M E Sherman
M Schiffman
P E Castle
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601272
P407
P577
2003-10-01T00:00:00Z